In just 10 years, Amicus Therapeutics has risen to the forefront of the biotechnology industry with a fresh approach to the treatment of genetic disorders and illnesses. The company’s own website boasts a wide range of drug therapies designed to treat a spectrum of rare genetic disorders.
Among the company’s greatest achievements, Amicus Therapeutics has recently unveiled a treatment for Fabry disease, a rare genetic disorder named for Johannes Fabry. The new course of treatments will be also be used to treat Pompe disease and other Lysosomal Storage Disorders through enzyme replacement therapy.
Developing a treatment plan for Lysosomal Storage Disorders is a tremendous advance, but it’s also the kind of thing this growing biotechnology company hopes to do regularly. Since its 2007 inception, Amicus Therapeutics has pledged to deliver the best possible treatments for people living with genetic diseases.
To maintain a vigilant focus on that directive, Amicus Therapeutics keeps a close eye on the community of families affected by rare and orphan genetic illnesses, providing them with support and offering new treatments, as they become available. In that vain, the biotechnology company is keeping an ear to the ground, looking for innovative ways to adapt new technologies and to outperform their own advances.
While Amicus Therapeutics’ own mission statement reveals a thirst for rapid advancement, the company is only limited by a desire for safety in their research and testing phases.
A code of conduct guides Amicus Therapeutics in all areas, from research and development to corporate decision making policies. A message from Patrik Florencio, Amicus Chief Compliance and Risk Officer, emphasizes that care for ethical actions on behalf of the company, ensuring that a concern for their patients won’t forsake greater concerns for the environments in which Amicus Therapeutics operates.
Speaking of their patients, Amicus Therapeutics takes their devotion to their patients into account, when considering new treatments. In searching for new treatments, Amicus collects research that will lead them toward more effective treatments for current and future patients. Incorporating patient input into developing each new therapy, Amicus Therapeutics remains at the forefront of the biotechnology industry .